Brilinta has been approved to crush to administer for the first time as an antiplatelet drug

The AstraZeneca’s ‘Brilinta (generic name: ticagrelor)’ has been approved to administer in a crushed form by the Ministry of Food andDrug Safety for the first time as an antiplatelet drug.

It is observed that the approval will increase administering convenience of patients having a swallowing disorder, an emergency situation where there is a difficulty to swallow or a problemswallowingwith old...